Cargando…

The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination had been demonstrated as an effective way to reduce the risk of coronavirus disease 2019 (COVID-19), and only a few vaccines suffered from SARS-CoV-2 infection. However, limited data concerning the clinical features...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianwu, Jiang, Na, Zeng, Qing-Lei, Zhang, Yue, He, Xinyuan, Chu, Yao, Jin, Wenni, Liu, Yi, Shi, Wan, Yang, Miao, He, Weihan, Han, Qing, Ma, Le, Xu, You, Guo, Yaling, Zhang, Lei, Ji, Fanpu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042076/
https://www.ncbi.nlm.nih.gov/pubmed/35498630
http://dx.doi.org/10.2147/IDR.S356460
_version_ 1784694601662070784
author Li, Jianwu
Jiang, Na
Zeng, Qing-Lei
Zhang, Yue
He, Xinyuan
Chu, Yao
Jin, Wenni
Liu, Yi
Shi, Wan
Yang, Miao
He, Weihan
Han, Qing
Ma, Le
Xu, You
Guo, Yaling
Zhang, Lei
Ji, Fanpu
author_facet Li, Jianwu
Jiang, Na
Zeng, Qing-Lei
Zhang, Yue
He, Xinyuan
Chu, Yao
Jin, Wenni
Liu, Yi
Shi, Wan
Yang, Miao
He, Weihan
Han, Qing
Ma, Le
Xu, You
Guo, Yaling
Zhang, Lei
Ji, Fanpu
author_sort Li, Jianwu
collection PubMed
description BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination had been demonstrated as an effective way to reduce the risk of coronavirus disease 2019 (COVID-19), and only a few vaccines suffered from SARS-CoV-2 infection. However, limited data concerning the clinical features of these vaccines infected with SARS-CoV-2 can be identified. METHODS: We retrospectively collected and analyzed epidemiological and clinical characteristics data of the imported COVID-19 cases who received Chinese inactivated vaccines abroad. Data were extracted from electronic medical records from a designated hospital in the Shaanxi Province of China between March 22 and May 17, 2021. RESULTS: Totally, 46 confirmed SARS-CoV-2 infection patients were enrolled. The mean age was 40.5 years (range 20–61), 41 (89.1%) are male. Eighteen (39.1%) patients were from Pakistan. Fourteen (30.4%) patients had at least one comorbidity. Forty (87.0%) and 6 cases were fully vaccinated and partly vaccinated. The time interval between vaccination and infection was 88 days (IQR, 33–123), 31 (67.4%) and 15 (32.6%) were asymptomatic and symptomatic cases, respectively. Fever (3/46, 6.5%) was the most common symptom; however, none had a body temperature higher than 38.0°C, and no severe case was observed. Notably, the rate of SARS-CoV-2 shedding discontinuation at 7 days after hospitalization in asymptomatic cases was higher than symptomatic one (93.5% vs 40%, P < 0.0001). CONCLUSION: Individuals who received Chinese inactivated vaccines abroad remain to have the probability of being infected with SARS-CoV-2, but all the vaccines infected with SARS-CoV-2 were asymptomatic or had mild symptoms with favorable clinical outcomes.
format Online
Article
Text
id pubmed-9042076
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90420762022-04-27 The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection Li, Jianwu Jiang, Na Zeng, Qing-Lei Zhang, Yue He, Xinyuan Chu, Yao Jin, Wenni Liu, Yi Shi, Wan Yang, Miao He, Weihan Han, Qing Ma, Le Xu, You Guo, Yaling Zhang, Lei Ji, Fanpu Infect Drug Resist Original Research BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination had been demonstrated as an effective way to reduce the risk of coronavirus disease 2019 (COVID-19), and only a few vaccines suffered from SARS-CoV-2 infection. However, limited data concerning the clinical features of these vaccines infected with SARS-CoV-2 can be identified. METHODS: We retrospectively collected and analyzed epidemiological and clinical characteristics data of the imported COVID-19 cases who received Chinese inactivated vaccines abroad. Data were extracted from electronic medical records from a designated hospital in the Shaanxi Province of China between March 22 and May 17, 2021. RESULTS: Totally, 46 confirmed SARS-CoV-2 infection patients were enrolled. The mean age was 40.5 years (range 20–61), 41 (89.1%) are male. Eighteen (39.1%) patients were from Pakistan. Fourteen (30.4%) patients had at least one comorbidity. Forty (87.0%) and 6 cases were fully vaccinated and partly vaccinated. The time interval between vaccination and infection was 88 days (IQR, 33–123), 31 (67.4%) and 15 (32.6%) were asymptomatic and symptomatic cases, respectively. Fever (3/46, 6.5%) was the most common symptom; however, none had a body temperature higher than 38.0°C, and no severe case was observed. Notably, the rate of SARS-CoV-2 shedding discontinuation at 7 days after hospitalization in asymptomatic cases was higher than symptomatic one (93.5% vs 40%, P < 0.0001). CONCLUSION: Individuals who received Chinese inactivated vaccines abroad remain to have the probability of being infected with SARS-CoV-2, but all the vaccines infected with SARS-CoV-2 were asymptomatic or had mild symptoms with favorable clinical outcomes. Dove 2022-04-22 /pmc/articles/PMC9042076/ /pubmed/35498630 http://dx.doi.org/10.2147/IDR.S356460 Text en © 2022 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Jianwu
Jiang, Na
Zeng, Qing-Lei
Zhang, Yue
He, Xinyuan
Chu, Yao
Jin, Wenni
Liu, Yi
Shi, Wan
Yang, Miao
He, Weihan
Han, Qing
Ma, Le
Xu, You
Guo, Yaling
Zhang, Lei
Ji, Fanpu
The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection
title The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection
title_full The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection
title_fullStr The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection
title_full_unstemmed The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection
title_short The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection
title_sort epidemiological, clinical features and outcomes of imported chinese covid-19 patients following inactivated vaccines injection
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042076/
https://www.ncbi.nlm.nih.gov/pubmed/35498630
http://dx.doi.org/10.2147/IDR.S356460
work_keys_str_mv AT lijianwu theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT jiangna theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT zengqinglei theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT zhangyue theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT hexinyuan theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT chuyao theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT jinwenni theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT liuyi theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT shiwan theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT yangmiao theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT heweihan theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT hanqing theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT male theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT xuyou theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT guoyaling theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT zhanglei theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT jifanpu theepidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT lijianwu epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT jiangna epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT zengqinglei epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT zhangyue epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT hexinyuan epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT chuyao epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT jinwenni epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT liuyi epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT shiwan epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT yangmiao epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT heweihan epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT hanqing epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT male epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT xuyou epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT guoyaling epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT zhanglei epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection
AT jifanpu epidemiologicalclinicalfeaturesandoutcomesofimportedchinesecovid19patientsfollowinginactivatedvaccinesinjection